Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

Durable Efficacy Across Extended Dosing IntervalsThe data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively.Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart Well tolerated across both dosing regimens, with a safety profile generally in line with ...